← boardnext 2027-08-31next 2028-12-31
VCNX
Vaccinex Inc.distress 6/10 · elevated risk$1.180%today-21% from 52w high
Lead: Metastatic Pancreatic Adenocarcinoma · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
-77%
Price & events
-11.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+1.7%
1W
+7.3%
1M
+24.2%
3M
-11.3%
6M
+12.4%
1Y
-84.7%
2Y
-99.8%
5Y
-99.7%
All
Overview
- Market Cap
- $3.16M
- Enterprise Value
- $2.05M
- Volume
- 0
- 52 Week Range
- $0.34 – $1.49
- Total Shares
- 2.68M
- Float Shares
- 1.18M
- Short %
- 3.23%
- % Held by Insiders
- 11.41%
- % Held by Institutions
- 45.01%
- Beta
- 0.64
Pipeline stages · 2 programs
VXCO-102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Avelumab and Pepinemab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-08-31 Estimated 50% readout ~2027-09-30 | Phase 1 | VXCO-102 | EBV | — | not yet recruiting |
| 2028-12-31 Estimated 50% readout ~2029-02-14 | Phase 1/2 | Avelumab and Pepinemab | Metastatic Pancreatic Adenocarcinoma | — | active not recruiting |
Catalyst news & presentations · 2
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Metastatic Pancreatic Adenocarcinoma
- none identified
Recent news
- 2026-07-08Vaccinex to Present New Biomarker Data From SIGNAL-AD Study Supporting Expanded Phase 2b Trial of Pepinemab in Early Alzheimer’s Disease - Quiver Quantitative
- 2026-07-08Vaccinex to Report New Biomarker Data and Plans for Phase - GlobeNewswire
- 2026-07-08Vaccinex to show new Alzheimer’s biomarker data in London - Stock Titan
- 2026-07-04If You Invested $1,000 in Vaccinex Inc (VCNX) - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.